Search research articles
Contact Us
Filters
Showing results (601-610 of 612) with videos related to
Page
of 62
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2025
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group
Florette K Hazard, Angus M S Toland, Serena Y Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2017
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Amy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Cell Metabolism
|
August 7, 2024
Intermittent clearance of p21-highly-expressing cells extends lifespan and confers sustained benefits to health and physical function
Binsheng Wang, Lichao Wang, Nathan S Gasek, et al.
Journal of the National Cancer Institute
|
March 9, 2024
Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study
Danielle Novetsky Friedman, Pamela J Goodman, Wendy M Leisenring, et al.
Cell Metabolism
|
November 23, 2021
Targeting p21<sup>Cip1</sup> highly expressing cells in adipose tissue alleviates insulin resistance in obesity
Lichao Wang, Binsheng Wang, Nathan S Gasek, et al.
Cell Metabolism
|
January 5, 2022
Targeting p21<sup>Cip1</sup> highly expressing cells in adipose tissue alleviates insulin resistance in obesity
Lichao Wang, Binsheng Wang, Nathan S Gasek, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 28, 1998
The International Neuroblastoma Risk Groups (INRG): a preliminary report
R P Castleberry, J Pritchard, P Ambros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2021
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium
Steven G DuBois, M Meaghan Granger, Susan Groshen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2018
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Steven G DuBois, Yael P Mosse, Elizabeth Fox, et al.
Journal of the National Cancer Institute
|
August 25, 2025
International neuroblastoma risk group consortium: a model of a networking for rare cancers
Susan L Cohn, Wendy B London, Gudrun Schleiermacher, et al.
Page
of 62
Search research articles
Search
Showing results (601-610 of 612) with videos related to
Sort By:
Page
of 62
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2025
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group
Florette K Hazard, Angus M S Toland, Serena Y Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2017
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Amy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Cell Metabolism
|
August 7, 2024
Intermittent clearance of p21-highly-expressing cells extends lifespan and confers sustained benefits to health and physical function
Binsheng Wang, Lichao Wang, Nathan S Gasek, et al.
Journal of the National Cancer Institute
|
March 9, 2024
Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study
Danielle Novetsky Friedman, Pamela J Goodman, Wendy M Leisenring, et al.
Cell Metabolism
|
November 23, 2021
Targeting p21<sup>Cip1</sup> highly expressing cells in adipose tissue alleviates insulin resistance in obesity
Lichao Wang, Binsheng Wang, Nathan S Gasek, et al.
Cell Metabolism
|
January 5, 2022
Targeting p21<sup>Cip1</sup> highly expressing cells in adipose tissue alleviates insulin resistance in obesity
Lichao Wang, Binsheng Wang, Nathan S Gasek, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 28, 1998
The International Neuroblastoma Risk Groups (INRG): a preliminary report
R P Castleberry, J Pritchard, P Ambros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2021
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium
Steven G DuBois, M Meaghan Granger, Susan Groshen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2018
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Steven G DuBois, Yael P Mosse, Elizabeth Fox, et al.
Journal of the National Cancer Institute
|
August 25, 2025
International neuroblastoma risk group consortium: a model of a networking for rare cancers
Susan L Cohn, Wendy B London, Gudrun Schleiermacher, et al.
Page
of 62